Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081707%3A_____%2F23%3A00577353" target="_blank" >RIV/68081707:_____/23:00577353 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15310/23:73620575
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/epdf/10.1002/anie.202310774" target="_blank" >https://onlinelibrary.wiley.com/doi/epdf/10.1002/anie.202310774</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/anie.202310774" target="_blank" >10.1002/anie.202310774</a>
Alternative languages
Result language
angličtina
Original language name
Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death
Original language description
A multitargeting prodrug (2) that releases gemcitabine, oxaliplatin, and doxorubicin in their active form in cancer cells is a potent cytotoxic agent with nM IC50s, it is highly selective to cancer cells with mean selectivity indices to human (136) and murine (320) cancer cells. It effectively induces release of DAMPs (CALR, ATP & HMGB1) in CT26 cells facilitating more efficient phagocytosis by J774 macrophages than the FDA drugs or their co-administration. The viability of CT26 cells co-cultured with J774 macrophages and treated with 2 was reduced by 32 % compared to the non-treated cells, suggesting a synergistic antiproliferative effect between the chemical and immune reactions. 2 inhibited in vivo tumor growth in two murine models (LLC and CT26) better than the FDA drugs or their co-administration with significantly lower body weight loss. Mice inoculated with CT26 cells treated with 2 showed slightly better tumor free survival than doxorubicin.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
<a href="/en/project/GA23-06307S" target="_blank" >GA23-06307S: Metal-based compounds as candidates for antimetastatic chemotherapy</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Angewandte Chemie - International Edition
ISSN
1433-7851
e-ISSN
1521-3773
Volume of the periodical
62
Issue of the periodical within the volume
42
Country of publishing house
DE - GERMANY
Number of pages
12
Pages from-to
—
UT code for WoS article
001063194900001
EID of the result in the Scopus database
2-s2.0-85170356579